$DRUG News
Last published 1w ago
- 1w agoDRUGBRIGHT MINDS BIOSCIENCES INVESTIGATION: DRUG Securities Investors Encouraged to Contact Kirby McInerney LLP About Their RightsGlobeNewswireNEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Bright Minds Biosciences ("Bright Minds" or the "Company") (NASDAQ:DRUG). The
- 1w agoDRUGBright Minds Biosciences Provides Update About Planned Study with BMB-101 in Developmental and Epileptic EncephalopathiesGlobeNewswireNEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company") announces that the U.S. Food and Drug Administration ("FDA")
- 2mo agoDRUGBright Minds Biosciences to Present at Upcoming ConferencesGlobeNewswireNEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG), a pioneering company focused on developing highly selective
- 3mo agoVTGNDRUGVistagen Appoints Douglas J. Williamson to its Board of DirectorsGlobeNewswireSOUTH SAN FRANCISCO, Calif., July 31, 2026 (GLOBE NEWSWIRE) -- Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and
- 5mo agoDRUGBright Minds Biosciences to Present at Jefferies Global Healthcare ConferenceGlobeNewswireNEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the
- 8mo agoDRUGBright Minds Biosciences to Present at Upcoming ConferencesGlobeNewswireNEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the
- 10mo agoDRUGBright Minds Biosciences Announces Closing of US$175 Million Public OfferingGlobeNewswireNEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company") today closed its recently announced public offering of 1,945,000 common shares in the
- 10mo agoDRUGBright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common StockGlobeNewswireNEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company") announces the pricing of its previously announced public offering of 1,945,000 common
- 10mo agoDRUGBright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026GlobeNewswire– Conference Call and Live Webcast at 8AM ET – NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company"), a clinical-stage biotechnology
- 11mo agoDRUGBright Minds Biosciences to Present at Piper Sandler 37th Annual Healthcare Conference and 2025 AES Annual MeetingGlobeNewswireNEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the
- 11mo agoDRUGBright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS)GlobeNewswire-- Tania Markovic MBBS PhD FRACP; Jennifer L. Miller, MD; Elizabeth Roof, H.S.P., M.A.; and Theresa V. Strong, PhD; distinguished global experts in PWS, will support the Company's PWS program, which was announced on
- 1y agoDRUGBright Minds Biosciences Initiates New Prader-Willi Syndrome (PWS) Program; KOL Event Scheduled for November 6THGlobeNewswire-- Company will host a webcast at 10am ET on November 6, 2025, to discuss its Phase 2a study to assess efficacy, safety and tolerability of BMB-101 (NOVA Study) for the treatment of patients with Prader-Willi Syndrome
- 1y agoDRUGBright Minds Biosciences to Present at Upcoming ConferencesGlobeNewswireNEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the
- 1y agoDRUGBright Minds Biosciences Announces BMB‑201 Outperforms Sumatriptan in Validated Preclinical Vascular Headache ModelGlobeNewswireNEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (NASDAQ:DRUG) today announced compelling preclinical results for its investigational compound BMB‑201, in a validated isosorbide dinitrate
- 1y agoDRUGBright Minds Biosciences to Present at Upcoming ConferencesGlobeNewswireNEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the
- 1y agoDRUGBright Minds Biosciences to Present at the 2025 Jefferies Global Healthcare ConferenceGlobeNewswireNEW YORK and VANCOUVER, British Columbia, May 28, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG), a pioneering company focused on developing highly
- 1y agoDRUGBright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&D Day on May 20, 2025GlobeNewswire- Key Opinion Leaders (KOLs) on Absence seizures include Dennis Dlugos, MD, Wendyl D'Souza, MBChB, MPH, FRACP, PhD, and Alexander Rotenberg, MD, PhD - VANCOUVER, British Columbia, May 20, 2025 (GLOBE NEWSWIRE) --
- 1y agoDRUGBright Minds Biosciences Announces Positive Findings from its DBA/2 Mouse Model Study Evaluating BMB-101GlobeNewswire- BMB-101 demonstrated a complete elimination of drop attacks in the DBA/2 mouse model - - The DBA/2 model is highly predictive of sudden unexpected death in epilepsy (SUDEP) - - Findings highlight BMB-101's
- 1y agoDRUGBright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 StudyGlobeNewswireVANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company"), a company focused on developing highly selective 5-HT2 agonists
- 1y agoDRUGBright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy ResearchGlobeNewswire– Dennis Dlugos, MD, MSCE; Jacqueline French, MD; Terrence O'Brien, MD; Jo Sourbron, MD, PhD, MPharm; and Joseph Sullivan, MD, bring decades of experience in epilepsy drug development and research to support
- 1y agoDRUGBright Minds Biosciences to Participate at Three Healthcare Conferences in MarchGlobeNewswireNEW YORK and VANCOUVER, British Columbia, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG), a pioneering company focused on developing highly
- 1y agoDRUGBright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical OfficerGlobeNewswire-- Dr. Collins brings extensive drug development and clinical expertise in epilepsy -- NEW YORK and VANCOUVER, British Columbia, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. ("Bright Minds," "BMB"
- 1y agoDRUGBright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual MeetingGlobeNewswire- Poster presentations on BMB-101 will focus on 5-HT2C functional selectivity and Phase 1 clinical data - NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (NASDAQ:DRUG), a pioneering company
- 2y agoDRUGBright Minds Biosciences Closes US$35 Million Non-Brokered Private PlacementGlobeNewswireVANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company") announces that further to its news release of October 18, 2024,
- 2y agoAIFFDRUGBright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG DataGlobeNewswireNEW YORK AND VANCOUVER, British Columbia, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (Bright Minds or the Company) (NASDAQ:DRUG), a biotechnology company focused on developing novel therapies for
- 2y agoDRUGBright Minds Biosciences Announces US$35 Million Non-Brokered Private PlacementGlobeNewswireNOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES VANCOUVER, British Columbia, Oct. 18,
- 2y agoDRUGBright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain modelsGlobeNewswireBMB-201 demonstrated dose-dependent efficacy in pain modelsBMB-201 demonstrated similar efficacy to morphine in several pain models NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc.
- 2y agoAIFFDRUGFirefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNA™ TechnologyGlobeNewswireTORONTO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly," or the "Company") (NASDAQ:AIFF), an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health
- 2y agoDRUGBright Minds Biosciences announces participation in upcoming scientific conferences and partnering eventsGlobeNewswireBright Minds Biosciences will present scientific posters about various programs in development, including BMB-101, BMB-201 and BMB-202Bright Minds Biosciences will participate in BIO Europe partnering event and Chicago
- 2y agoDRUGBright Minds Biosciences to Host Investor & Analyst KOL Event on September 25thGlobeNewswireBright Minds Biosciences announced the initiation of Phase 2 clinical trial of BMB-101 in a group of drug-resistant epilepsies and will discuss the details of the BREAKTHROUGH clinical trial on September 25th.The event
- 2y agoDRUGBright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic EncephalopathyPR NewswireBright Minds Biosciences announces Phase 2 Clinical trial to evaluate BMB-101 in a group of drug-resistant epilepsy disorders with high unmet needs...
- 3y agoBDRXCRDFDRUGLLY+1Biotech Market Update: Global Pharmaceuticals Market Expected to Reach $1.5 Trillion by Year's EndPR NewswireFinancialNewsMedia.com News Commentary
- 3y agoDRUGBright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101GlobeNewswire-- BMB-101 is a highly selective and potent 5-HT2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders -- qEEG
- 3y agoDRUGBright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101GlobeNewswire-- BMB-101 is a highly selective and potent 5-HT2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders -- BMB-101
- 3y agoDRUGBright Minds Announces Effective Date of Share ConsolidationGlobeNewswireVANCOUVER, British Columbia, July 11, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company"), a biotechnology company focused on developing novel drugs for the
- 3y agoDRUGBright Minds Announces Proposed Share ConsolidationGlobeNewswireVANCOUVER, British Columbia, June 22, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company"), a biotechnology company focused on developing novel drugs for the
- 3y agoDRUGBright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202GlobeNewswire-- BMB-202 is a highly selective 5-HT2A agonist that exhibits a more than 30-fold selectivity over 5-HT2C and more than 500-fold selectivity over 5-HT2B -- -- BMB-202 is the first clinical candidate from an extensive
- 3y agoDRUGBright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin ResearchGlobeNewswire— Presentation entitled "BMB-101: A selective 5-HT2C agonist in clinical trials with therapeutic utility" — — First-in-human Phase 1 trial for lead program, BMB-101, is underway in Australia — VANCOUVER,
- 3y agoDRUGBright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023GlobeNewswire-- First-in-human Phase 1 trial for lead program, BMB-101, a highly selective 5-HT2C agonist, is underway in Australia -- -- Company has transitioned from a discovery to a development organization – -- Company to
- 3y agoDRUGBright Minds Biosciences Announces Non-Executive Director AppointmentGlobeNewswireNOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES VANCOUVER, British Columbia, Feb. 17,
- 3y agoDRUGBright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee RequirementsGlobeNewswireVANCOUVER, British Columbia, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company") announces that it has received a letter (the "Deficiency Letter")
- 3y agoDRUGBright Minds Biosciences Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price DeficiencyGlobeNewswireVANCOUVER, British Columbia, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company") announces that it has received a notification letter (the
- 3y agoDRUGBright Minds Biosciences Announces Resignation of Board MemberGlobeNewswireVANCOUVER, British Columbia, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG) (CSE:DRUG), a biotechnology company focused on developing novel drugs for
- 3y agoDRUGBright Minds Biosciences Announces Closing of Non-Brokered Private PlacementGlobeNewswireTHIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, Dec. 02,
- 3y agoDRUGBright Minds Biosciences Announces Non-Brokered Private PlacementGlobeNewswireTHIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, Nov. 28,
- 3y agoDRUGBright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D., Ph.D. as Chief Medical OfficerGlobeNewswire-- Dr. Smith is a 20-year pharmaceutical industry veteran with extensive central nervous system ("CNS") clinical development expertise -- VANCOUVER, British Columbia, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Bright Minds
- 4y agoACHCDRUGHCALFST+1New Study Reveals Psychedelic Drugs Can Be Almost as Life-Changing as Near-Death ExperiencesPR NewswireFN Media Group Presents Microsmallcap.com Market Commentary NEW YORK, Oct. 5, 2022 /PRNewswire/ -- A new study undertaken by experts at John Hopkins University School of Medicine has revealed that taking psychedelics can have the same transformational
- 4y agoDRUGBright Minds Biosciences Announces Appointment of Doug Williamson to Board of DirectorsGlobeNewswireNOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES VANCOUVER, British Columbia, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Brigh
- 4y agoDRUGBright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet SyndromeGlobeNewswireVANCOUVER, British Columbia, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG) (CSE:DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsyc
- 4y agoDRUGBright Minds Biosciences Announces Closing of $4 Million Unit OfferingGlobeNewswireTHIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Bright